Ergot derivatives for Parkinsonism

D. B. Calne, A. C. Williams, John Nutt, A. Neophytides, T. Eisler, P. F. Teychenne

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The response of Parkinsonism to three ergot derivatives which modify dopaminergic transmission was studied. CF 25-397 behaved more as an antagonist than an agonist. Lergotrile was an agonist with therapeutic properties marred by prominent hepatotoxicity. Bromocriptine is an effective anti-Parkinsonian agent, particularly useful in patients with prominent dyskinesia or 'on-off' reactions to levodopa; in most patients optimal results have been obtained by combining from 40 to 90 mg of bromocriptine daily with approximately 60% of the previous maximal dose of levodopa. Unfortunately, only some 50% of patients tolerate long-term bromocriptine therapy, but all adverse reactions have been dose dependent and reversible.

Original languageEnglish (US)
Pages (from-to)25-26
Number of pages2
JournalMedical Journal of Australia
Volume2
Issue numberSuppl. 3
StatePublished - 1979
Externally publishedYes

Fingerprint

Bromocriptine
Parkinsonian Disorders
Levodopa
Dyskinesias
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Calne, D. B., Williams, A. C., Nutt, J., Neophytides, A., Eisler, T., & Teychenne, P. F. (1979). Ergot derivatives for Parkinsonism. Medical Journal of Australia, 2(Suppl. 3), 25-26.

Ergot derivatives for Parkinsonism. / Calne, D. B.; Williams, A. C.; Nutt, John; Neophytides, A.; Eisler, T.; Teychenne, P. F.

In: Medical Journal of Australia, Vol. 2, No. Suppl. 3, 1979, p. 25-26.

Research output: Contribution to journalArticle

Calne, DB, Williams, AC, Nutt, J, Neophytides, A, Eisler, T & Teychenne, PF 1979, 'Ergot derivatives for Parkinsonism', Medical Journal of Australia, vol. 2, no. Suppl. 3, pp. 25-26.
Calne DB, Williams AC, Nutt J, Neophytides A, Eisler T, Teychenne PF. Ergot derivatives for Parkinsonism. Medical Journal of Australia. 1979;2(Suppl. 3):25-26.
Calne, D. B. ; Williams, A. C. ; Nutt, John ; Neophytides, A. ; Eisler, T. ; Teychenne, P. F. / Ergot derivatives for Parkinsonism. In: Medical Journal of Australia. 1979 ; Vol. 2, No. Suppl. 3. pp. 25-26.
@article{667994e4b7274d6daa75947abaeb9e44,
title = "Ergot derivatives for Parkinsonism",
abstract = "The response of Parkinsonism to three ergot derivatives which modify dopaminergic transmission was studied. CF 25-397 behaved more as an antagonist than an agonist. Lergotrile was an agonist with therapeutic properties marred by prominent hepatotoxicity. Bromocriptine is an effective anti-Parkinsonian agent, particularly useful in patients with prominent dyskinesia or 'on-off' reactions to levodopa; in most patients optimal results have been obtained by combining from 40 to 90 mg of bromocriptine daily with approximately 60{\%} of the previous maximal dose of levodopa. Unfortunately, only some 50{\%} of patients tolerate long-term bromocriptine therapy, but all adverse reactions have been dose dependent and reversible.",
author = "Calne, {D. B.} and Williams, {A. C.} and John Nutt and A. Neophytides and T. Eisler and Teychenne, {P. F.}",
year = "1979",
language = "English (US)",
volume = "2",
pages = "25--26",
journal = "Medical Journal of Australia",
issn = "0025-729X",
publisher = "Australasian Medical Publishing Co. Ltd",
number = "Suppl. 3",

}

TY - JOUR

T1 - Ergot derivatives for Parkinsonism

AU - Calne, D. B.

AU - Williams, A. C.

AU - Nutt, John

AU - Neophytides, A.

AU - Eisler, T.

AU - Teychenne, P. F.

PY - 1979

Y1 - 1979

N2 - The response of Parkinsonism to three ergot derivatives which modify dopaminergic transmission was studied. CF 25-397 behaved more as an antagonist than an agonist. Lergotrile was an agonist with therapeutic properties marred by prominent hepatotoxicity. Bromocriptine is an effective anti-Parkinsonian agent, particularly useful in patients with prominent dyskinesia or 'on-off' reactions to levodopa; in most patients optimal results have been obtained by combining from 40 to 90 mg of bromocriptine daily with approximately 60% of the previous maximal dose of levodopa. Unfortunately, only some 50% of patients tolerate long-term bromocriptine therapy, but all adverse reactions have been dose dependent and reversible.

AB - The response of Parkinsonism to three ergot derivatives which modify dopaminergic transmission was studied. CF 25-397 behaved more as an antagonist than an agonist. Lergotrile was an agonist with therapeutic properties marred by prominent hepatotoxicity. Bromocriptine is an effective anti-Parkinsonian agent, particularly useful in patients with prominent dyskinesia or 'on-off' reactions to levodopa; in most patients optimal results have been obtained by combining from 40 to 90 mg of bromocriptine daily with approximately 60% of the previous maximal dose of levodopa. Unfortunately, only some 50% of patients tolerate long-term bromocriptine therapy, but all adverse reactions have been dose dependent and reversible.

UR - http://www.scopus.com/inward/record.url?scp=0018777641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018777641&partnerID=8YFLogxK

M3 - Article

C2 - 34083

AN - SCOPUS:0018777641

VL - 2

SP - 25

EP - 26

JO - Medical Journal of Australia

JF - Medical Journal of Australia

SN - 0025-729X

IS - Suppl. 3

ER -